Atara Biotherapeutics (ATRA) Stock Price, News & Analysis

Company Overview

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Key Stats

• Today's Range: $12.23 to $12.75
• 50-Day Range: $7.72 to $13.02
• 52-Week Range: $5.01 to $18.70
• Volume: 33,045 shs
• Average Volume: 109,081 shs
• Market Capitalization: $86.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.00
• Consensus Rating: Moderate Buy

Atara Biotherapeutics Stock Analysis - MarketRank™

Atara Biotherapeutics scored higher than 91% of companies evaluated by MarketBeat, and ranked 92nd out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Atara Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Atara Biotherapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Atara Biotherapeutics are expected to grow in the coming year, from ($10.39) to ($10.04) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Atara Biotherapeutics is -28.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Atara Biotherapeutics is -28.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.03% of the float of Atara Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Atara Biotherapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Atara Biotherapeutics has recently decreased by 6.84%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Atara Biotherapeutics does not currently pay a dividend.

Dividend Growth

Atara Biotherapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.87

Percentage of Shares Shorted

5.03% of the float of Atara Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Atara Biotherapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Atara Biotherapeutics has recently decreased by 6.84%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: N/A

News Sentiment

Atara Biotherapeutics has a news sentiment score of 1.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Atara Biotherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $856,839.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 4.00% of the stock of Atara Biotherapeutics is held by insiders.

Percentage Held by Institutions

70.90% of the stock of Atara Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ATRA Stock Analysis - Frequently Asked Questions

How have ATRA shares performed this year?

Atara Biotherapeutics' stock was trading at $13.31 at the beginning of 2025. Since then, ATRA shares have decreased by 7.1% and is now trading at $12.36.

How were Atara Biotherapeutics' earnings last quarter?

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) issued its earnings results on Monday, August, 11th. The biotechnology company reported $0.19 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.51. The biotechnology company earned $17.58 million during the quarter, compared to analysts' expectations of $4.23 million. Atara Biotherapeutics had a negative trailing twelve-month return on equity of 8.34% and a net margin of 3.07%.

When did Atara Biotherapeutics' stock split?

Atara Biotherapeutics shares reverse split on Thursday, June 20th 2024.The 1-25 reverse split was announced on Thursday, June 20th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Who are Atara Biotherapeutics' major shareholders?

Atara Biotherapeutics' top institutional shareholders include Geode Capital Management LLC (1.01%), Marshall Wace LLP (0.71%), Bank of America Corp DE (0.11%) and Raymond James Financial Inc. (0.06%). Insiders that own company stock include Innovation Ltd Panacea, Anhco Nguyen, Pascal Touchon, Eric J Hyllengren, Yanina Grant-Huerta, Jill Henrich, Carol Giltner Gallagher, Jakob Dupont, Amar Murugan, William K Heiden and Utpal Koppikar.
View institutional ownership trends.

How do I buy shares of Atara Biotherapeutics?

Shares of ATRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Atara Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Atara Biotherapeutics investors own include Agenus (AGEN), CRISPR Therapeutics (CRSP), Pfizer (PFE), Athersys (ATHX), Advanced Micro Devices (AMD), Bristol Myers Squibb (BMY) and FuelCell Energy (FCEL).

Company Calendar

• Last Earnings: 8/11/2025
• Today: 9/03/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ATRA
• CIK: 1604464
• Web: www.atarabio.com
• Phone: (805) 623-4211
• Fax: N/A
• Employees: 330
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Atara Biotherapeutics: $21.00
• High Price Target: $25.00
• Low Price Target: $17.00
• Potential Upside/Downside: +70.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.43)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$85.40 million
• Net Margins: 3.07%
• Pretax Margin: 3.05%
• Return on Equity: -8.34%
• Return on Assets: 6.61%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.70
• Quick Ratio: 1.70

Sales & Book Value

• Annual Sales: $188.67 million
• Price / Sales: 0.46
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($4.99) per share
• Price / Book: -2.47

Miscellaneous

• Outstanding Shares: 7,023,000
• Free Float: 6,742,000
• Market Cap: $86.59 million
• Optionable: Optionable
• Beta: 0.22